These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 34729812)

  • 1. 2E-Decene-4,6-diyn-1-ol-acetate inhibits osteoclastogenesis through mitogen-activated protein kinase-c-Fos-NFATc1 signalling pathways.
    Park YR; Su XD; Shrestha SK; Yang SY; Soh Y
    Clin Exp Pharmacol Physiol; 2022 Mar; 49(3):341-349. PubMed ID: 34729812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ganomycin I from Ganoderma lucidum attenuates RANKL-mediated osteoclastogenesis by inhibiting MAPKs and NFATc1.
    Tran PT; Dat NT; Dang NH; Van Cuong P; Lee S; Hwangbo C; Van Minh C; Lee JH
    Phytomedicine; 2019 Mar; 55():1-8. PubMed ID: 30668419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
    Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
    J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ameloblastin attenuates RANKL-mediated osteoclastogenesis by suppressing activation of nuclear factor of activated T-cell cytoplasmic 1 (NFATc1).
    Chaweewannakorn W; Ariyoshi W; Okinaga T; Fujita Y; Maki K; Nishihara T
    J Cell Physiol; 2019 Feb; 234(2):1745-1757. PubMed ID: 30105896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein E inhibits osteoclast differentiation via regulation of c-Fos, NFATc1 and NF-κB.
    Kim WS; Kim HJ; Lee ZH; Lee Y; Kim HH
    Exp Cell Res; 2013 Feb; 319(4):436-46. PubMed ID: 23246654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aster saponin A
    Su XD; Yang SY; Shrestha SK; Soh Y
    J Vet Sci; 2022 Jul; 23(4):e47. PubMed ID: 35698806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Desoxyrhapontigenin inhibits RANKL‑induced osteoclast formation and prevents inflammation‑mediated bone loss.
    Tran PT; Park DH; Kim O; Kwon SH; Min BS; Lee JH
    Int J Mol Med; 2018 Jul; 42(1):569-578. PubMed ID: 29693149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kalkitoxin Reduces Osteoclast Formation and Resorption and Protects against Inflammatory Bone Loss.
    Li L; Yang M; Shrestha SK; Kim H; Gerwick WH; Soh Y
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Parthenolide inhibits osteoclast differentiation and bone resorbing activity by down-regulation of NFATc1 induction and c-Fos stability, during RANKL-mediated osteoclastogenesis.
    Kim JY; Cheon YH; Yoon KH; Lee MS; Oh J
    BMB Rep; 2014 Aug; 47(8):451-6. PubMed ID: 24314143
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin 29 inhibits RANKL-induced osteoclastogenesis via activation of JNK and STAT, and inhibition of NF-κB and NFATc1.
    Peng Q; Luo A; Zhou Z; Xuan W; Qiu M; Wu Q; Xu L; Kong X; Zhang M; Tan W; Xue M; Wang F
    Cytokine; 2019 Jan; 113():144-154. PubMed ID: 30001863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bajijiasu Abrogates Osteoclast Differentiation via the Suppression of RANKL Signaling Pathways through NF-κB and NFAT.
    Hong G; Zhou L; Shi X; He W; Wang H; Wei Q; Chen P; Qi L; Tickner J; Lin L; Xu J
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Zanthoxylum bungeanum seed oil inhibits RANKL-induced osteoclastogenesis by suppressing ERK/c-JUN/NFATc1 pathway and regulating cell cycle arrest in RAW264.7 cells.
    He F; Luo S; Liu S; Wan S; Li J; Chen J; Zuo H; Pei X
    J Ethnopharmacol; 2022 May; 289():115094. PubMed ID: 35149133
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Agelasine D suppresses RANKL-induced osteoclastogenesis via down-regulation of c-Fos, NFATc1 and NF-κB.
    Kang MR; Jo SA; Yoon YD; Park KH; Oh SJ; Yun J; Lee CW; Nam KH; Kim Y; Han SB; Yu J; Rho J; Kang JS
    Mar Drugs; 2014 Nov; 12(11):5643-56. PubMed ID: 25421321
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stattic inhibits RANKL-mediated osteoclastogenesis by suppressing activation of STAT3 and NF-κB pathways.
    Li CH; Xu LL; Jian LL; Yu RH; Zhao JX; Sun L; Du GH; Liu XY
    Int Immunopharmacol; 2018 May; 58():136-144. PubMed ID: 29587202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bergapten suppresses RANKL-induced osteoclastogenesis and ovariectomy-induced osteoporosis via suppression of NF-κB and JNK signaling pathways.
    Chen G; Xu Q; Dai M; Liu X
    Biochem Biophys Res Commun; 2019 Feb; 509(2):329-334. PubMed ID: 30579598
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Acteoside suppresses RANKL-mediated osteoclastogenesis by inhibiting c-Fos induction and NF-κB pathway and attenuating ROS production.
    Lee SY; Lee KS; Yi SH; Kook SH; Lee JC
    PLoS One; 2013; 8(12):e80873. PubMed ID: 24324641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Norisoboldine suppresses osteoclast differentiation through preventing the accumulation of TRAF6-TAK1 complexes and activation of MAPKs/NF-κB/c-Fos/NFATc1 Pathways.
    Wei ZF; Tong B; Xia YF; Lu Q; Chou GX; Wang ZT; Dai Y
    PLoS One; 2013; 8(3):e59171. PubMed ID: 23536866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxidation derivative of (-)-epigallocatechin-3-gallate (EGCG) inhibits RANKL-induced osteoclastogenesis by suppressing RANK signaling pathways in RAW 264.7 cells.
    Xu H; Liu T; Li J; Xu J; Chen F; Hu L; Zhang B; Zi C; Wang X; Sheng J
    Biomed Pharmacother; 2019 Oct; 118():109237. PubMed ID: 31376653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-κB and MAPK pathways.
    Gan K; Yang L; Xu L; Feng X; Zhang Q; Wang F; Tan W; Zhang M
    Int Immunopharmacol; 2016 Jun; 35():294-300. PubMed ID: 27085680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Constant hypoxia inhibits osteoclast differentiation and bone resorption by regulating phosphorylation of JNK and IκBα.
    Ma Z; Yu R; Zhao J; Sun L; Jian L; Li C; Liu X
    Inflamm Res; 2019 Feb; 68(2):157-166. PubMed ID: 30604211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.